Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLP1R | P43220 | 8/20 | 0.46 |
| ▸ | FOLH1 | Q04609 | 5/20 | 0.36 |
| ▸ | EPOR | P19235 | 2/20 | 0.34 |
| ▸ | PLK1 | P53350 | 1/20 | 0.34 |
| ▸ | AKT1 | P31749 | 1/20 | 0.33 |
| ▸ | MGLL | Q99685 | 1/20 | 0.33 |
| ▸ | SIRT2 | Q8IXJ6 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22967376 | 0.93 | GLP1R (0.42) | GLP1RFOLH1PLK1AKT1MGLL | |
| SCHEMBL16329790 | 0.91 | GLP1R (0.51) | GLP1RFOLH1EPORPLK1 | |
| SCHEMBL19541810 | 0.91 | GLP1R (0.51) | GLP1RFOLH1EPORPLK1 | |
| SCHEMBL16329599 | 0.91 | GLP1R (0.51) | GLP1RFOLH1EPORPLK1 | |
| SCHEMBL19541901 | 0.91 | GLP1R (0.50) | GLP1RFOLH1AKT1SIRT2 | |
| SCHEMBL16329594 | 0.90 | GLP1R (0.52) | GLP1RFOLH1EPORPLK1AKT1 | |
| SCHEMBL22515210 | 0.90 | GLP1R (0.49) | GLP1RFOLH1EPORAKT1SIRT2 | |
| SCHEMBL26562244 | 0.90 | GLP1R (0.47) | GLP1RFOLH1EPORAKT1SIRT2 | |
| SCHEMBL16329539 | 0.89 | GLP1R (0.45) | GLP1RFOLH1EPORPLK1AKT1 | |
| SCHEMBL19541902 | 0.88 | GLP1R (0.49) | GLP1RFOLH1EPORAKT1SIRT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10947289-B2 | Glyco-modified atrial natriuretic peptide | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2021-03-16 | — | — | US | disclosed |
| US-20210040170-A1 | GLYCO-MODIFIED ATRIAL NATRIURETIC PEPTIDE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2021-02-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10947289-B2 | Glyco-modified atrial natriuretic peptide | NPPA, NPR1, NPR3 | GLP1R 15/4885FOLH1 2196/4885EPOR 2475/4885 |
| US-20210040170-A1 | GLYCO-MODIFIED ATRIAL NATRIURETIC PEPTIDE | NPPA, NPR1, NPR3 | GLP1R 15/4885FOLH1 2196/4885EPOR 2475/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.